Remove Chemotherapy Remove Compounding Remove Drug Development
article thumbnail

STAT+: Pharmacists can make shortage drugs, but at what cost?

STAT

Pharmacists increasingly are being asked to make drugs in bulk for hospitals that are in short supply, and they’re even beginning to make chemotherapies. Hospitals’ reliance on pharmacist-made drugs, a practice called compounding, has risen in step with worsening drug shortages.

article thumbnail

Pluvicto™ offers survival benefits for metastatic prostate cancer

European Pharmaceutical Review

The PSMAfore results are the second positive set of data for Pluvicto in a Phase III trial, after the VISION clinical trial, where PSMA–positive mCRPC patients who received Pluvicto plus standard of care (SoC) after ARPI and taxane-based chemotherapy, showed statistically significant reduction in risk of death. The PSMAfore study.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Evaluating methods targeting Protein-Protein Interactions

pharmaphorum

Understanding the mechanism of PPIs and developing methods to target aberrant ones has been a key strategy in drug development. The interface is highly hydrophobic, hence any compounds containing water would be repelled. The flat interface remains the primary challenge facing the development of PPI modulators.

article thumbnail

ACD-440 by AlzeCure Pharma for Neuropathic Pain (Neuralgia): Likelihood of Approval

Pharmaceutical Technology

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

article thumbnail

There is a large pipeline of CAR-T cell therapies for diffuse large B-cell lymphoma

Pharmaceutical Technology

By 2028, the market is expected to reach $25 billion, with a compound annual growth rate (CAGR) of 46.6%. The standard first-line treatment for DLBCL is a chemotherapy regimen, alongside the monoclonal antibody rituximab. There are a total of 124 companies involved in CAR-T cell drug development for this indication.

article thumbnail

PROTAC development gains momentum, but clinical performance is poor

Pharmaceutical Technology

This makes early R&D less risky, as many lead compounds are discontinued due to inadequate pharmacokinetic profiles and require excessively high dosages to be pharmaceutically active. Faslodex will be administered in the control arm of the Phase III study, allowing for direct comparison between the two ER degraders.

Dosage 59
article thumbnail

Beating the Big C

Pharmaceutical Technology

Despite the enormous growth being enjoyed by the global oncology market, potential cancer cures are left on laboratory shelves on a regular basis, according to Dr Victoria John, head of clinical partnerships at Cancer Research UK’s Drug Development Office. “Companies shelve research on a regular basis,” she says.